000087714 001__ 87714
000087714 005__ 20200716101528.0
000087714 0247_ $$2doi$$a10.1016/j.autrev.2018.12.006
000087714 0248_ $$2sideral$$a110712
000087714 037__ $$aART-2019-110712
000087714 041__ $$aeng
000087714 100__ $$aAlijotas-Reig, J.
000087714 245__ $$aThe European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases
000087714 260__ $$c2019
000087714 5060_ $$aAccess copy available to the general public$$fUnrestricted
000087714 5203_ $$aAim: To analyse the clinical features, laboratory data and foetal-maternal outcomes, and follow them up on a cohort of 1000 women with obstetric antiphospholipid syndrome (OAPS).
Methods: The European Registry of OAPS became a registry within the framework of the European Forum on Antiphospholipid Antibody projects and was placed on a website in June 2010. Thirty hospitals throughout Europe have collaborated to carry out this registry. Cases with obstetric complaints related to antiphospholipid antibodies (aPL) who tested positive for aPL at least twice were included prospectively and retrospectively. The seven-year survey results are reported. Results: 1000 women with 3553 episodes were included of which 2553 were historical and 1000 were latest episodes. All cases fulfilled the Sydney classification criteria. According to the laboratory categories, 292 (29.2%) were in category I, 357 (35.7%) in IIa, 224 (22.4%) in IIb and 127 (12.7%) in IIc. Miscarriages were the most prevalent clinical manifestation in 386 cases (38.6%). Moreover, the presence of early preeclampsia (PE) and early foetal growth restriction (FGR) appeared in 181 (18.1%) and 161 (16.1%), respectively. In this series, 448 (44.8%) women received the recommended OAPS treatment. Patients with recommended treatment had a good live-birth rate (85%), but worse results (72.4%) were obtained in patients with any treatment (low-dose aspirin (LDA) or low-molecular-weight heparin (LMWH) not on recommended schedule, while patients with no treatment showed a poor birth rate (49.6%).
Conclusion: In this series, recurrent miscarriage is the most frequent poor outcome. To avoid false-negative diagnoses, all laboratory category subsets were needed. OAPS cases have very good foetal-maternal outcomes when treated. Results suggest that we were able to improve our clinical practice to offer better treatment and outcomes to OAPS patients.
000087714 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000087714 590__ $$a7.767$$b2019
000087714 591__ $$aIMMUNOLOGY$$b17 / 158 = 0.108$$c2019$$dQ1$$eT1
000087714 592__ $$a2.281$$b2019
000087714 593__ $$aImmunology and Allergy$$c2019$$dQ1
000087714 593__ $$aImmunology$$c2019$$dQ1
000087714 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/acceptedVersion
000087714 700__ $$aEsteve-Valverde, E.
000087714 700__ $$aFerrer-Oliveras, R.
000087714 700__ $$0(orcid)0000-0002-9868-6498$$aSáez-Comet, L.$$uUniversidad de Zaragoza
000087714 700__ $$aLefkou, E.
000087714 700__ $$aMekinian, A.
000087714 700__ $$aBelizna, C.
000087714 700__ $$aRuffatti, A.
000087714 700__ $$aTincani, A.
000087714 700__ $$aMarozio, L.
000087714 700__ $$aEspinosa, G.
000087714 700__ $$aCervera, R.
000087714 700__ $$ade Carolis, S.
000087714 700__ $$aLatino, O.
000087714 700__ $$aLLurba, E.
000087714 700__ $$aMeroni, P.L.
000087714 700__ $$aChighizola, C.B.
000087714 700__ $$aGerosa, M.
000087714 700__ $$aPengo, V.
000087714 700__ $$aLundelin, K.
000087714 700__ $$aRovere-Querini, P.
000087714 700__ $$aCanti, V.
000087714 700__ $$aMayer-Pickel, K.
000087714 700__ $$aReshetnyak, T.
000087714 700__ $$aHoxha, A.
000087714 700__ $$aTabacco, S.
000087714 700__ $$aStojanovich, L.
000087714 700__ $$aGogou, V.
000087714 700__ $$aVaroudis, A.
000087714 700__ $$aArnau, A.
000087714 700__ $$aRuiz-Hidalgo, D.
000087714 700__ $$aTrapé, J.
000087714 700__ $$aSos, L.
000087714 700__ $$aStoppani, C.
000087714 700__ $$aMartí-Cañamares, A.
000087714 700__ $$aFarran-Codina, I.
000087714 700__ $$afor, the, EUROAPS, Study, Group
000087714 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000087714 773__ $$g18, 4 (2019), 406-414$$pAutoimmun. Rev.$$tAUTOIMMUNITY REVIEWS$$x1568-9972
000087714 8564_ $$s135620$$uhttps://zaguan.unizar.es/record/87714/files/texto_completo.pdf$$yPostprint
000087714 8564_ $$s47691$$uhttps://zaguan.unizar.es/record/87714/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000087714 909CO $$ooai:zaguan.unizar.es:87714$$particulos$$pdriver
000087714 951__ $$a2020-07-16-09:32:15
000087714 980__ $$aARTICLE